Search - tctmd.com

Displaying 1 - 20 of 794

Sort: Relevancy | Date

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

News Conference News ACC 2026

Oral PCSK9 Inhibitor Bests Other Nonstatin Therapies for LDL-Lowering

Michael O'Riordan

April 01, 2026

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

News Conference News ACC 2026

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

Michael O'Riordan

March 30, 2026

Deferring PCI Until After TAVI Safe, Reduces Bleeding: PRO-TAVI

News Conference News ACC 2026

Deferring PCI Until After TAVI Safe, Reduces Bleeding: PRO-TAVI

Yael L. Maxwell

March 30, 2026

Impella Support in High-Risk PCI Doesn’t Help, Might Harm: CHIP-BCIS3

News Conference News ACC 2026

Impella Support in High-Risk PCI Doesn’t Help, Might Harm: CHIP-BCIS3

Yael L. Maxwell

March 29, 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

News Conference News ACC 2026

PCSK9 Inhibitor Very Effective in High-risk Patients Without ASCVD: VESALIUS-CV

Michael O'Riordan

March 29, 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

What’s Going to Be Hot at ACC 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

SOLVE-TAVI: Patient Sex, for the Most Part, Doesn’t Sway Outcomes by Valve Type

News Conference News CRT 2026

SOLVE-TAVI: Patient Sex, for the Most Part, Doesn’t Sway Outcomes by Valve Type

March 16, 2026

AGENT IDE Midterm Results Still Give DCB an Edge for In-Stent Restenosis

News Conference News CRT 2026

AGENT IDE Midterm Results Still Give DCB an Edge for In-Stent Restenosis

March 11, 2026

Large Variability in Use of Invasive Strategy for Type 1 NSTEMI: NCDR

News Conference News CRT 2026

Large Variability in Use of Invasive Strategy for Type 1 NSTEMI: NCDR

Michael O'Riordan

March 11, 2026

DOBERMANN: Dobutamine and Tocilizumab Show Promise in Pre-Shock Patients

News Conference News CRT 2026

DOBERMANN: Dobutamine and Tocilizumab Show Promise in Pre-Shock Patients

March 09, 2026

CRT 2026: What to Expect in Washington, DC

News Conference News CRT 2026

CRT 2026: What to Expect in Washington, DC

March 04, 2026

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

News Conference News AHA 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

November 13, 2025

Lower Mortality With Complete Revascularization in Acute MI Patients With MVD

News Conference News AHA 2025

Lower Mortality With Complete Revascularization in Acute MI Patients With MVD

Michael O'Riordan

November 12, 2025

Beta-blockers Not Helpful After MI in Patients With Preserved EF

News Conference News AHA 2025

Beta-blockers Not Helpful After MI in Patients With Preserved EF

Yael L. Maxwell

November 12, 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

News Conference News AHA 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

November 09, 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

News Conference News AHA 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

November 08, 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

November 08, 2025

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

News Conference News TCT 2025

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

Yael L. Maxwell

November 07, 2025

SAVE-PCI: Small-Bore Percutaneous VAD Matches IABP in High-risk PCI

News Conference News TCT 2025

SAVE-PCI: Small-Bore Percutaneous VAD Matches IABP in High-risk PCI

November 06, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.